Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingExpanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingA Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingSafety and Efficacy of OBX-115 in Advanced Solid Tumors

GCC19CART for Patients With Metastatic Colorectal Cancer

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingGCC19CART for Patients With Metastatic Colorectal Cancer

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingStudy of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingA Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingCD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingA Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingThe American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingCD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
  • Go to the previous page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 22
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us